Guideline #	Guideline Name	Type of Change	Brief Description of Guideline Change	Reason for Changes
ECG 3031	Adcetris (brentuximab vedotin)	No clinical change	1) Updated contraindications/warnings section 2) Updated maximum dosages in exclusion criteria 3) Updated references	Annual Review
ECG 3032	Brukinsa (zanubrutinib)	No clinical change	1) Updated maximum dosage form quantities in exclusion criteria 2) Updated references	Annual Review
ECG 3034	Cosela (trilaciclib)	No clinical change	Updated references	Annual Review
ECG 3036	Enjaymo (sutimlimab-jome)	No clinical change	Updated references	Annual Review
ECG 3037	Fotivda (tivozanib)	No clinical change	Updated references	Annual Review
ECG 3038	Gazyva (obinutuzumab)	No clinical change	1) Updated cycle duration limit in exclusion criteria 2) Updated contraindications/warnings section 3) Updated references	Annual Review
ECG 3040	Gomekli (mirdametinib)	No clinical change	1) Updated contraindications/warnings section 2) Updated references	Annual Review
ECG 3041	Jakafi (ruxolitinib)	No clinical change	Updated references	Annual Review
ECG 3042	Lorbrena (lorlatinib)	No clinical change	Updated references	Annual Review
ECG 3043	Orserdu (elacestrant)	No clinical change	Updated references	Annual Review
ECG 3044	Photofrin (porfimer)	No clinical change	Updated references	Annual Review
ECG 3045	Revlimid (lenalidomide)	No clinical change	1) Updated indication section 2) Updated contraindications/warnings section 3) Updated references	Annual Review
ECG 3046	Rituximab Products	No clinical change	1) Updated contraindications/warnings section 2) Updated references	Annual Review
ECG 3047	Romvimza (vimseltinib)	No clinical change	Updated references	Annual Review
ECG 3048	Tepmetko (tepotinib)	No clinical change	Updated references	Annual Review
ECG 3049	Tevimbra (tislelizumab-jsgr)	Positive	1) Added colorectal cancer to indication section 2) Added gastric cancer to indication section 3) Updated esophageal cancer indication section 4) Updated exclusion criteria 5) Updated references	Annual Review
ECG 3050	Tukysa (tucatinib)	No clinical change	1) Updated maximum dosage form quantities in exclusion criteria 2) Updated references	Annual Review
ECG 3051	Venclexta (venetoclax)	Positive	1) Updated indication section for previously untreated CLL/SLL without del(17p) or TP53 mutation in combination with acalabrutinib 2) Updated contraindications/warnings section 3) Updated maximum dosage and dosage form quantities in exclusion criteria 4) Updated references	Annual Review
ECG 3053	Xpovio (selinexor)	No clinical change	1) Updated maximum dosage form quantities in exclusion criteria 2) Updated references	Annual Review
ECG 3025	Yescarta (axicabtagene ciloleucel)	No clinical change	On February 6, 2026, Gilead and Kite Pharma announced that the FDA has approved updated prescribing information for Yescarta (axicabtagene ciloleucel) by removing the previous Limitations of Use in patients with relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL). 1) Verbiage removed from policy in July 2023 2) Updated references	New FDA Drug/ Indication
ECG 3159	Keytruda and Keytruda Qlex (pembrolizumab IV/SC)	Positive	On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens. 1) Added Ovarian Cancer to indication section 2) Updated Breast Cancer indication to include use in combination with Trodelvy (sacituzumab govitecan-hziy) in adult members for the first-line treatment of recurrent or metastatic (Stage IV) TNBC with PD-L1 CPS ≥10 regardless of germline BRCA 1/2 PV status 3) Updated references	New FDA Drug/ Indication
ECG 3005	Calquence (acalabrutinib)	Positive	On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 1) Updated indication section to include previously untreated CLL/SLL without del(17p) or TP53 mutation 2) Updated references	New FDA Drug/ Indication
ECG 3160	Darzalex and Darzalex Faspro (daratumumab IV/SC)	Positive	On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 1) Added combination of Darzalex Faspro + Tecvayli (teclistamab-cqyv) for RRMM after 1-3 prior therapies 2) Updated references	New FDA Drug/ Indication

ECG 3243	Tecvayli (teclistamab-cqyv)	Positive	On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 1) Added combination of Darzalex Faspro + Tecvayli (teclistamab-cqyv) for RRMM after 1-3 prior therapies 2) Updated exclusion criteria 3) Updated references	New FDA Drug/ Indication
ECG 3073	Trastuzumab Products, Pertuzumab Products, and Phesgo	Positive	1) Removed from Breast Cancer indication section for neoadjuvant/adjuvant setting: - Node negative (N0) and tumor stage T1 HER-2 positive breast cancer - Adjuvant treatment in members who did not receive neoadjuvant therapy 2) Added to Breast Cancer indication section for neoadjuvant/adjuvant setting: - The member has node negative and/or tumor stage ≥ T1 HER-2 positive breast cancer AND trastuzumab/trastuzumab biosimilar + chemotherapy may be used as neoadjuvant or adjuvant treatment 3) Added new indication for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer in combination with Enhertu (fam-trastuzumab deruxtecan-nxki) 4) Updated references	Other
ECG 3156	Nubeqa (darolutamide)	Positive	1) Added "members should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had bilateral orchiectomy" to indication section 2) Updated references	Other
ECG 3261	Trodelvy (sacituzumab govitecan-hziy)	Positive	1) Updated Breast Cancer indication to include: - Use in combination with Keytruda/Keytruda Qlex (pembrolizumab IV/SC) in adult members for the first-line treatment of recurrent or metastatic (Stage IV) TNBC with PD-L1 CPS ≥10 regardless of germline BRCA 1/2 PV status - Use in adult members for the first-line treatment of recurrent or metastatic (Stage IV) TNBC with PD-L1 CPS <10 and no germline BRCA 1/2 PV 2) Updated exclusion criteria 3) Updated references	Other